Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / NOTE 5.750% 8/0
-
Market price (% of par)
-
101.61%
-
Total 13F principal
-
$49,273,000
-
Principal change
-
-$1,286,000
-
Total reported market value
-
$50,102,000
-
Number of holders
-
10
-
Value change
-
-$871,328
-
Number of buys
-
3
-
Number of sells
-
5
Institutional Holders of INOTEK PHARMACEUTICALS CORP - NOTE 5.750% 8/0 as of Q2 2018
As of 30 Jun 2018,
INOTEK PHARMACEUTICALS CORP - NOTE 5.750% 8/0 was held by
10 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$49,273,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, Polygon Management Ltd., ORBIMED ADVISORS LLC, KINGDON CAPITAL MANAGEMENT, L.L.C., ACUTA CAPITAL PARTNERS, LLC, Bruce & Co., Inc., Telemetry Investments, L.L.C., CREDIT SUISSE AG/, and Verition Fund Management LLC.
This page lists
10
institutional bondholders reporting positions
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.